Amicus Therapeutics Engages Investors with November Presentations
Amicus Therapeutics Engages Investors with November Presentations
Amicus Therapeutics, a prominent entity in the biotechnology sector, has announced plans for key presentations at several investor conferences this November. This engagement promises to foster greater awareness of the company’s innovative approaches to treating rare diseases and seeking investment opportunities.
Upcoming Conferences
The first major event is the Guggenheim Healthcare Innovation Conference taking place in Boston. Scheduled for November 12, 2024, the presentation will start at 2:30 p.m. ET. This conference is known for bringing together leaders in healthcare and enabling impactful discussions.
Jefferies London Healthcare Conference
Continuing their outreach, Amicus Therapeutics will also participate in the Jefferies London Healthcare Conference on November 19, 2024, at 8:00 a.m. GMT. This international platform offers an opportunity to connect with European investors and industry leaders, underlining the company’s commitment to a global perspective in rare disease treatment.
Additional Engagements
In addition to these two conferences, the management team will attend the J.P. Morgan Equity Opportunities Forum on November 13, 2024. This forum is highly regarded in the finance and investment community, providing valuable networking opportunities and targeted discussions on equity strategies and market dynamics.
About Amicus Therapeutics
Amicus Therapeutics is a driven biotechnology company focused on discovering and delivering groundbreaking therapies for individuals living with rare diseases. The company is dedicated to developing first- or best-in-class medicines, striving to meet the needs of patients who often have limited options available. Their emphasis on patient-centric care demonstrates their commitment to improving lives through innovative treatment methodologies.
Commitment to a Patient-Centric Approach
At the core of Amicus Therapeutics' mission lies an unwavering dedication to patients. The company continuously seeks to expand its pipeline of high-quality medicines, emphasizing the importance of collaboration and transparency in the development of therapies. Patients are not only at the center of their operations but are also vital stakeholders in guiding research initiatives.
Contact Information
For interested parties wishing to connect with Amicus Therapeutics, the following contacts are available:
Investors:
Amicus Therapeutics
Andrew Faughnan
Vice President, Investor Relations
afaughnan@amicusrx.com
(609) 662-3809
Media:
Amicus Therapeutics
Diana Moore
Head of Global Corporate Affairs and Communications
dmoore@amicusrx.com
(609) 662-5079
Frequently Asked Questions
What events will Amicus Therapeutics participate in this November?
Amicus Therapeutics will participate in the Guggenheim Healthcare Innovation Conference and Jefferies London Healthcare Conference, among others.
Where can I find more information about Amicus Therapeutics?
More information can be found on the company's official website and through their investor relations section.
Who are the key contacts for Amicus Therapeutics?
Key contacts include Andrew Faughnan for investor relations and Diana Moore for media inquiries.
What is the focus of Amicus Therapeutics?
Amicus Therapeutics focuses on developing and delivering innovative treatments for patients with rare diseases.
How does Amicus Therapeutics approach patient care?
The company emphasizes a patient-centric approach, ensuring that the needs and perspectives of patients guide their research and development initiatives.
About Investors Hangout
Investors Hangout is a leading online stock forum for financial discussion and learning, offering a wide range of free tools and resources. It draws in traders of all levels, who exchange market knowledge, investigate trading tactics, and keep an eye on industry developments in real time. Featuring financial articles, stock message boards, quotes, charts, company profiles, and live news updates. Through cooperative learning and a wealth of informational resources, it helps users from novices creating their first portfolios to experts honing their techniques. Join Investors Hangout today: https://investorshangout.com/
Disclaimer: The content of this article is solely for general informational purposes only; it does not represent legal, financial, or investment advice. Investors Hangout does not offer financial advice; the author is not a licensed financial advisor. Consult a qualified advisor before making any financial or investment decisions based on this article. The author's interpretation of publicly available data shapes the opinions presented here; as a result, they should not be taken as advice to purchase, sell, or hold any securities mentioned or any other investments. The author does not guarantee the accuracy, completeness, or timeliness of any material, providing it "as is." Information and market conditions may change; past performance is not indicative of future outcomes. If any of the material offered here is inaccurate, please contact us for corrections.
